Reata Pharmaceuticals (NASDAQ:RETA – Get Rating) had its target price raised by Stifel Nicolaus from $105.00 to $115.00 in a research report report published on Thursday, The Fly reports. A number of other research analysts have also commented on RETA. Citigroup lifted their price objective on shares of Reata Pharmaceuticals from $53.00 to $120.00 and […]
Reata Pharmaceuticals, Inc. (NASDAQ:RETA – Get Rating) – Investment analysts at SVB Leerink cut their Q1 2023 earnings per share (EPS) estimates for shares of Reata Pharmaceuticals in a report issued on Tuesday, April 11th. SVB Leerink analyst J. Schwartz now expects that the company will post earnings of ($2.22) per share for the quarter, […]
Emerald Advisers LLC raised its position in shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA – Get Rating) by 26.3% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 679,772 shares of the company’s stock after purchasing an additional 141,520 shares during the period. Reata Pharmaceuticals […]
Reata Pharmaceuticals (NASDAQ:RETA – Get Rating) had its price objective raised by Cantor Fitzgerald from $121.00 to $138.00 in a research note published on Monday morning, The Fly reports. The firm currently has an overweight rating on the stock. Cantor Fitzgerald also issued estimates for Reata Pharmaceuticals’ FY2022 earnings at ($8.54) EPS and FY2023 earnings […]